Leinco Technologies

Anti-Mouse CD279 (PD-1) (Clone RMP1-14) - Purified in vivo PLATINUM™ Functional Grade

Product Code:
 
LEI-P372
Product Group:
 
Primary Antibodies
Host Type:
 
Rat
Antibody Isotype:
 
IgG2a κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
RMP1-14
Regulatory Status:
 
RUO
Target Species:
 
Mouse
Applications:
  • Blocking
  • Functional Study
  • In Vivo Assay
  • Western Blot (WB)
Shipping:
 
2-8°C
Storage:
 
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-P372-1.0mg1.0 mg£283.00
Quantity:
LEI-P372-5.0mg5.0 mg£456.00
Quantity:
LEI-P372-25mg25 mg£1,335.00
Quantity:
LEI-P372-50mg50 mg£1,938.00
Quantity:
LEI-P372-100mg100 mg£2,741.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Concentration:
?7.0 mg/ml
Conjugate/Tag/Label:
Purified in vivo Functional Grade, in vivo PLATINUM™
Format:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Immunogen:
Mouse PD-1 transfected BHK cells
Long Description:
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
NCBI Gene:
18566
Purity:
?95% monomer by analytical SEC, >95% by SDS Page
Target:
PD-1

References

1.) Ardolino, M. et al. (2018) J Clin Invest. 128(10):4654-4668. PubMed 2.) Schreiber, RD. et al. (2017) Cancer Immunol Res. 5(2):106-117. 3.) Honjo, T. et al. (1992) EMBO J. 11:3887. 4.) Gubin et al. (2018) Cell. 175:1014?1030 Journal Link 5.) Renner et al. (2019) Cell Reports. 29:135?150 Journal Link 6.) Gubin, M. et al. (2018) Cell 175(4):1014-1030.e19 Journal Link